2025-06-06T14:25:01-05:00 2024-12-31 521711839 COUNCILOR BUCHANAN & MITCHELL PC 7910 WOODMONT AVE STE 500 BETHESDA MD 20814 990 2024-01-01 020542064 ASSOCIATION OF CLINICAL RESEARCH ORGANIZATIONS ASSO 2024649340 601 NEW JERSEY AVE NW 350 WASHINGTON DC 20001 DOUG PEDDICORD EXECUTIVE DIRECTOR 2024649340 2025-06-06 1 0 DOMINICK V BELLIA P00560402 3019860600 2025-06-08 2024 2025-03-06 01:10:19Z ACRO DOUG PEDDICORD 601 NEW JERSEY AVE NW 350 WASHINGTON DC 20001 3714667 0 X WWW.ACROHEALTH.ORG X 2002 DC SEE SCHEDULE O. 11 11 0 0 0 0 0 0 2375000 2162500 94015 151261 0 0 2469015 2313761 0 210000 0 0 0 0 0 0 0 2091418 2227532 2091418 2437532 377597 -123771 3426449 3293943 55128 47623 3371321 3246320 X ACRO AND ITS MEMBERS ADVOCATE ON A GLOBAL BASIS FOR SAFE, ETHICAL, HIGH-QUALITY MEDICAL RESEARCH SO PATIENTS CAN BENEFIT FROM THE DEVELOPMENT OF NEW TREATMENTS AND THERAPIES. 0 0 THE ASSOCIATION OF CLINICAL RESEARCH ORGANIZATIONS (ACRO) REPRESENTS THE WORLD'S LEADING CLINICAL RESEARCH ORGANIZATIONS AND CLINICAL TECHNOLOGY COMPANIES. ACRO'S MEMBERS PROVIDE SPECIALIZED SERVICES THAT ARE INTEGRAL TO THE DEVELOPMENT OF DRUGS, BIOLOGICS, AND MEDICAL DEVICES. ACRO ADVANCES CLINICAL OUTSOURCING TO IMPROVE THE QUALITY, EFFICIENCY, AND SAFETY OF BIOMEDICAL RESEARCH. ACRO'S PRIORITIES IN 2024 INCLUDED: 1. A US FOCUS ON REGULATORY ADVOCACY, SPECIFICALLY REPRESENTING CLINICAL RESEARCH AND CLINICAL TECHNOLOGY COMPANIES IN POLICY DISCUSSIONS WITH THE FDA. (CONTINUED IN SCHEDULE O) 2. EU ADVOCACY FOCUSED ON REPRESENTING THE INDUSTRY IN POLICY DISCUSSIONS WITH THE EUROPEAN COMMISSION, THE EUROPEAN MEDICINES AGENCY, AND UK AND OTHER EU MEMBER STATE REGULATORY BODIES.3. REPRESENTING MEMBER COMPANIES TO OTHER REGULATORS AND INDUSTRY STAKEHOLDERS SUCH AS CUSTOMERS. 0 0 0 1 0 0 0 0 0 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 0 0 0 0 0 0 0 1 0 0 0 0 0 0 0 0 1 19 0 1 0 0 0 0 0 1 1 0 0 0 0 0 X 11 11 0 1 0 0 1 1 0 1 0 0 0 0 0 0 0 0 0 0 X ASSOCIATION OF CLINICIAL RESEARCH ORGANIZATIONS 2024649340 601 NEW JERSEY AVE NW 350 WASHINGTON DC 20001 X PEYTON HOWELL CHAIR 1.00 X X 0 0 0 CYNTHIA VERST PAST CHAIR 1.00 X X 0 0 0 JIM REILLY VICE-CHAIR 1.00 X X 0 0 0 MIKE CROWLEY SECRETARY 1.00 X X 0 0 0 ARI FELDMAN TREASURER 1.00 X X 0 0 0 GREG LICHOLAI BOARD MEMBER 1.00 X 0 0 0 LISA MONEYMAKER BOARD MEMBER 1.00 X 0 0 0 JOSEPH SCHMIDT BOARD MEMBER (Q1-Q3 2024) 1.00 X 0 0 0 KAREN KAUCIC BOARD MEMBER 1.00 X 0 0 0 SEEMA VERMA BOARD MEMBER 1.00 X 0 0 0 CATHERINE GREGOR BOARD MEMBER 1.00 X 0 0 0 GADI SAARONY BOARD MEMBER 1.00 X 0 0 0 JIM CORRIGAN BOARD MEMBER 1.00 X 0 0 0 CASSANDRA KENNEDY BOARD MEMBER 1.00 X 0 0 0 DOUGLAS PEDDICORD EXECUTIVE DIRECTOR 30.00 X 0 0 0 0 0 0 0 0 0 0 WASHINGTON HEALTH STRATEGIES GROUP 601 NEW JERSEY AVE NW 350 WASHINGTON DC 20001 ASSOCIATION MANAGEMENT AND LOBBYING SERV 1275000 BEEKEEPER GROUP LLC 1101 14TH STREET NW SUITE 200 WASHINGTON DC 20005 COMMUNICATIONS AND CONSULTING SERVICES 189240 2 MEMBERSHIP DUES 900099 2137500 2137500 ACRO FORUM DUES 900099 25000 25000 2162500 121167 121167 1431000 1400906 30094 30094 30094 2313761 2162500 0 151261 210000 1275000 14441 41623 14085 37440 31079 183684 10649 4113 MARKETING/COMMUNICATION 201222 FLEXIBLE RESOURCES 190119 D&I GRANTS PROGRAM 64242 MEMORIAL FUND: GLEN DE 50000 109835 2437532 413725 493304 354452 8774 75000 225000 10729 4250 63650 39449 34850 24201 2537693 2538414 3426449 3293943 55128 47623 55128 47623 X 3371321 3246320 3371321 3246320 3426449 3293943 -123771 -1230 0 X 1 X 0 0 0 0 0 0 2162500 180625 -65860 114765 151375 -36610 63650 39449 24201 24201 X PART X, LINE 2: ACRO BELIEVES IT HAS APPROPRIATE SUPPORT FOR ANY TAX POSITIONS TAKEN, AND, AS SUCH, DOES NOT HAVE ANY UNCERTAIN TAX POSITIONS THAT ARE MATERIAL TO THE FINANCIAL STATEMENTS. ACRO RECOGNIZES INTEREST EXPENSE AND PENALTIES RELATED TO INCOME TAXES ON UNCERTAIN TAX POSITIONS IN MISCELLANEOUS EXPENSE ON THE FINANCIAL STATEMENTS. ACRO REPORTED NO PENALTIES OR INTEREST RELATED TO INCOME TAXES ON UNCERTAIN TAX POSITIONS FOR THE YEARS ENDED DECEMBER 31, 2024 AND 2023. TAX YEARS PRIOR TO 2021 FOR ACRO ARE NO LONGER SUBJECT TO EXAMINATION BY THE IRS OR BY THE TAX JURISDICTION OF THE DISTRICT OF COLUMBIA. 1 NEBRASKA CANCER SPECIALISTS 17201 WRIGHT STREET SUITE 200 OMAHA NE 68130 470754790 20000 0 TO INCREASE CLINICAL TRIAL PARTICIPANT DIVERSITY AT THEIR SITE. BROOKLYN CLINICAL RESEARCH 150 LENOX ROAD BROOKLYN NY 11226 992468368 20000 0 TO INCREASE CLINICAL TRIAL PARTICIPANT DIVERSITY AT THEIR SITE. SUPERIOR CLINICAL RESEARCH LLC 96 REEDER BRANCH DRIVE CLAYTON NC 27520 861201032 20000 0 TO INCREASE CLINICAL TRIAL PARTICIPANT DIVERSITY AT THEIR SITE. SMART CURES CLINICAL RESEARCH LLC 215 N STATE COLLEGE BLVD SUITE A ANAHEIM CA 92806 851868373 50000 0 TO INCREASE CLINICAL TRIAL PARTICIPANT DIVERSITY AT THEIR SITE. RANDOMIZE NOW 1325 COMMERCE DRIVE SUITE 200 PEACHTREE CITY GA 30269 854268052 20000 0 TO INCREASE CLINICAL TRIAL PARTICIPANT DIVERSITY AT THEIR SITE. K2 MEDICAL RESEARCH LLC 101 SOUTHHALL LANE MAITLAND FL 32751 861831937 40000 0 TO INCREASE CLINICAL TRIAL PARTICIPANT DIVERSITY AT THEIR SITE. PREFERRED PRIMARY CARE PHYSICIANS INC 701 TECHNOLOGY DRIVE SUITE 150 CANSONSBURG PA 15317 251742085 40000 0 TO INCREASE CLINICAL TRIAL PARTICIPANT DIVERSITY AT THEIR SITE. WASHINGTON HEALTH STRATEGIES GROUP MANAGEMENT COMPANY 1275000 DOUG PEDDICORD, THE EXECUTIVE DIRECTOR OF THE ORGANIZATION, IS A 5% OR MORE OWNER AND OFFICER/KEY EMPLOYEE OF WASHINGTON HEALTH STRATEGIES GROUP, WHICH PROVIDES MANAGEMENT AND ADVOCACY REPRESENTATION SERVICES TO THE ORGANIZATION. 0 FORM 990, PART VI, SECTION A, LINE 3 THE BUSINESS OPERATIONS OF ACRO ARE MANAGED BY WASHINGTON HEALTH STRATEGIES GROUP. FORM 990, PART VI, SECTION A, LINE 6 REGULAR MEMBERS. REGULAR MEMBERSHIP IN THE ASSOCIATION SHALL BE LIMITED TO A SOLE PROPRIETORSHIP, PARTNERSHIP, OR CORPORATION AMONG WHOSE CORE BUSINESSES IS THAT OF A CLINICAL RESEARCH AND TECHNOLOGY ORGANIZATION WHICH SUPPORTS CLINICAL RESEARCH OR TRIALS FOR THE PHARMACEUTICAL, MEDICAL DEVICE OR BIO-TECHNOLOGY INDUSTRIES, AND HAS AN INTEREST IN THE ASSOCIATION, SUPPORTS ITS PURPOSE, AND OTHERWISE QUALIFIES FOR MEMBERSHIP UNDER CRITERIA ESTABLISHED BY THE BOARD OF DIRECTORS FROM TIME TO TIME IN ITS SOLE DISCRETION. REGULAR MEMBERS SHALL BE ENTITLED TO VOTE ON ALL MATTERS COMING BEFORE THE MEMBERSHIP AND TO APPOINT THE DIRECTORS AS PROVIDED FOR IN ARTICLE V, SECTION 4 OF THESE BYLAWS. CORPORATE OR PARTNERSHIP MEMBERS SHALL HAVE THE RIGHT TO APPOINT A DIRECTOR AND CAST ITS VOTE IN THE ASSOCIATION THROUGH ONE DESIGNATED REPRESENTATIVE WHO SHALL BE A NATURAL PERSON. ASSOCIATE MEMBERS. ASSOCIATE MEMBERSHIP IN THE ASSOCIATION SHALL BE LIMITED TO A SOLE PROPRIETORSHIP, PARTNERSHIP, LIMITED LIABILITY COMPANY OR CORPORATION AMONG WHOSE CORE BUSINESSES IS THAT OF A CLINICAL RESEARCH AND TECHONOLOGY ORGANIZATION WHICH SUPPORTS CLINICAL RESEARCH AND/OR TRIALS FOR THE PHARMACEUTICAL, MEDICAL DEVICE OR BIO-TECHNOLOGY INDUSTRIES, AND HAS AN INTEREST IN THE ASSOCIATION, SUPPORTS ITS PURPOSE, AND OTHERWISE QUALIFIES FOR MEMBERSHIP UNDER CRITERIA ESTABLISHED BY THE BOARD OF DIRECTORS FROM TIME TO TIME IN ITS SOLE DISCRETION. FORM 990, PART VI, SECTION A, LINE 7A EACH PARTNERSHIP OR CORPORATE MEMBER SHALL ACT THROUGH AND BE REPRESENTED BY A SINGLE DESIGNATED REPRESENTATIVE OF THAT PARTNERSHIP OR CORPORATION. THE DESIGNATED REPRESENTATIVE SHALL BE IDENTIFIED TO THE CHAIR OF THE ASSOCIATION UPON MEMBERSHIP APPROVAL AND SUCH DESIGNATION SHALL CONTINUE UNTIL THE CHAIR IS NOTIFIED IN WRITING OF ANY CHANGE. THE DESIGNATED REPRESENTATIVE SHALL ATTEND, VOTE AND REPRESENT THE MEMBER PARTNERSHIP OR CORPORATION AT ANY MEETING OF THE ASSOCIATION. THE DESIGNATED REPRESENTATIVE SHALL RECEIVE CORRESPONDENCE FROM ASSOCIATION ON BEHALF OF THE PARTNERSHIP OR CORPORATE MEMBER. FORM 990, PART VI, SECTION A, LINE 8B COMMITTEES DO NOT ACT ON BEHALF OF THE GOVERNING BODY. FORM 990, PART VI, SECTION B, LINE 11B ACRO ENGAGES AN INDEPENDENT ACCOUNTING FIRM TO CONDUCT A BIENNIAL AUDIT OF THE FINANCIAL RECORDS OF THE ORGANIZATION. THE AUDIT PROCESS BEGINS APPROXIMATELY 30 DAYS AFTER THE END OF THE FISCAL YEAR AND IS COMPLETED WITHIN 60 DAYS. WHEN THE REVIEW OF THE FINANCIAL RECORDS IS COMPLETE, THE INDEPENDENT ACCOUNTING FIRM ISSUES THE AUDIT TO ACRO, WHICH IS REVIEWED BY THE ORGANIZATION'S MANAGEMENT FIRM AND ITS TREASURER. THE FINANCIAL AUDIT REPORT IS DISTRIBUTED TO THE BOARD OF DIRECTORS FOR REVIEW AND ACCEPTANCE DURING A REGULAR MEETING OF THE BOARD. ONCE THE AUDITED FINANCIAL STATEMENTS ARE ACCEPTED BY THE BOARD OF DIRECTORS, THE FORM 990 (TAX RETURN) IS THEN PREPARED BY ACRO'S ACCOUNTANTS. COPIES OF THE COMPLETED FORM 990, WITH SUPPORTING SCHEDULES AND FOOTNOTES, ARE DISTRIBUTED TO THE TREASURER AND LEGAL COUNSEL FOR REVIEW. ANY CORRECTIONS OR CHANGES WILL BE NOTED AND ADDRESSED. THE FINAL FORM 990 IS THEN FILED USING E-FILE OR PAPER RETURN PROCEDURES BY THE PUBLISHED DEADLINE. THE BOARD OF DIRECTORS IS INFORMED OF THE FILING DURING ITS NEXT REGULAR MEETING, AS WELL OF THE AVAILABILITY OF COPIES OF THE COMPLETED FORM 990 UPON REQUEST. FORM 990, PART VI, SECTION B, LINE 12 ACRO ENGAGES AN OUTSIDE FIRM TO MANAGE ITS ACTIVITIES. THE POLICY OF THIS FIRM IS TO COMPLY WITH THE DISTRICT OF COLUMBIA BAR ASSOCIATION CODE OF ETHICS AND THE CODE OF PROFESSIONAL CONDUCT, WHICH SET FORTH POLICIES ON THE ABOVE ISSUES. FORM 990, PART VI, SECTION C, LINE 19 ACRO'S GOVERNING DOCUMENTS (BYLAWS AND ARTICLES OF INCORPORATION), ANNUAL RETURNS AND FINANCIAL STATEMENTS ARE AVAILABLE UPON REQUEST.